Latest Articles

LLTs Exposure Time and Major Vascular Risk Reduction

New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua^®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.

Meta Analysis of apoB Lowering and CV Risk Reduction Among Different LLTs

Galimberti F, et al. Poster presented at the 91st European Atherosclerosis Society congress (EAS) 2023.

LDL-C The Only Causal Risk Factor for ASCVD

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

LLTs and Antithrombotic Therapy in PAD

Lipid Management in Patients with Diabetes Mellitus

LDL-C Targets in Patients with Heterozygous Familial Hypercholesterolemia

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines